Vol 82, Supp. I (2024): Zeszyty Edukacyjne 1/2024
Opinie i stanowiska ekspertów
Published online: 2024-09-18
Postępowanie w chorobach sercowo-naczyniowych u pacjentów z otyłością — stanowisko ekspertów
Abstract
Not available
References
- GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: A systematic analysis for the global burden of disease study 2021. Lancet. 2024; 403(10440): 2162–2203.
- Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: Systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016; 353: i2156.
- Kim MS, Kim WJ, Khera AV, et al. Association between adiposity and cardiovascular outcomes: An umbrella review and meta-analysis of observational and Mendelian randomization studies. Eur Heart J. 2021; 42(34): 3388–3403.
- Jayedi A, Khan T, Aune D, et al. Body fat and risk of all-cause mortality: A systematic review and dose-response meta-analysis of prospective cohort studies. Int J Obes (Lond). 2022; 46(9): 1573–1581.
- Marcks N, Aimo A, Januzzi JL, et al. Re-appraisal of the obesity paradox in heart failure: A meta-analysis of individual data. Clin Res Cardiol. 2021; 110(8): 1280–1291.
- Blumenthal JA, Hinderliter AL, Smith PJ, et al. Effects of lifestyle modification on patients with resistant hypertension: Results of the TRIUMPH randomized clinical trial. Circulation. 2021; 144(15): 1212–1226.
- Glover BM, Hong KL, Dagres N, et al. Impact of body mass index on the outcome of catheter ablation of atrial fibrillation. Heart. 2019; 105(3): 244–250.
- NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: A pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024; 403(10431): 1027–1050.
- Płaczkiewicz-Jankowska E, Czupryniak L, Gajos G, et al. Management of obesity in the times of climate change and COVID-19: An interdisciplinary expert consensus report. Pol Arch Intern Med. 2022; 132(3).
- Stepaniak U, Micek A, Waśkiewicz A, et al. Prevalence of general and abdominal obesity and overweight among adults in Poland. Results of the WOBASZ II study (2013–2014) and comparison with the WOBASZ study (2003–2005). Pol Arch Med Wewn. 2016; 126(9): 662–671.
- Kozieł P, Jankowski P, Mirek-Bryniarska E, et al. Obesity in patients with established coronary artery disease over a 20-year period (1997–2017). Pol Arch Intern Med. 2021; 131(1): 26–32.
- Jankowski P, Kozieł P, Pająk A. Body mass index and waist circumference in patients with established coronary artery disease over a 20-year period. Cardiol J. 2023; 30(1): 150–152.
- Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
- Suthahar N, Meems LMG, Withaar C, et al. Relative fat mass, a new index of adiposity, is strongly associated with incident heart failure: Data from PREVEND. Sci Rep. 2022; 12(1): 147.
- Benn M, Marott SCW, Tybjærg-Hansen A, et al. Obesity increases heart failure incidence and mortality: Observational and Mendelian randomization studies totalling over 1 million individuals. Cardiovasc Res. 2023; 118(18): 3576–3585.
- Mechanick JI, Hurley DL, Garvey WT. Adiposity-based chronic disease as a new diagnostic term: The American Association of Clinical Endocrinologists and American College of Endocrinology position statement. Endocr Pract. 2017; 23(3): 372–378.
- Severinsen MCK, Pedersen BK. Muscle-organ crosstalk: The emerging roles of myokines. Endocr Rev. 2020; 41(4): 594–609.
- Lopez-Jimenez F, Almahmeed W, Bays H, et al. Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation. Eur J Prev Cardiol. 2022; 29(17): 2218–2237.
- Busebee B, Ghusn W, Cifuentes L, et al. Obesity: A review of pathophysiology and classification. Mayo Clin Proc. 2023; 98(12): 1842–1857.
- Dobrowolski P, Prejbisz A, Kuryłowicz A, et al. Metabolic syndrome — a new definition and management guidelines: A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, "Club 30" Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons. Arch Med Sci. 2022; 18(5): 1133–1156.
- Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: Mechanistic links between common co-morbidities. J Endocrinol. 2016; 229(2): R67–R81.
- Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association. Circulation. 2023; 148(20): 1606–1635.
- Ordulj I, Šarić F, Tandara M, et al. Visceral and ectopic abdominal fat effect on the calcification of the abdominal aorta and its branches-an MSCT study. Life (Basel). 2023; 14(1).
- Kivimäki M, Strandberg T, Pentti J, et al. Body-mass index and risk of obesity-related complex multimorbidity: An observational multicohort study. Lancet Diabetes Endocrinol. 2022; 10(4): 253–263.
- Yofoglu LK, Karachalias F, Georgakis MK, et al. Association of pressure wave reflections with left ventricular mass: A systematic review and meta-analysis. Hypertension. 2023; 80(3): e29–e42.
- Fong S, Pabis K, Latumalea D, et al. Principal component-based clinical aging clocks identify signatures of healthy aging and targets for clinical intervention. Nat Aging. 2024; 4(8): 1137–1152.
- Bąk-Sosnowska M, Białkowska M, Bogdański P, et al. Zalecenia kliniczne dotyczące postępowania u chorych na otyłość 2022 — stanowisko Polskiego Towarzystwa Leczenia Otyłości. Med Prakt wyd. specj. maj 2022: 1–87.
- Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: A clinical practice guideline. CMAJ. 2020; 192(31): E875–E891.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023; 389(24): 2221–2232.
- Acosta A, Camilleri M, Abu Dayyeh B, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: A pragmatic trial in an obesity clinic. Obesity (Silver Spring). 2021; 29(4): 662–671.
- Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015; 8(6): 402–424.
- Stevens VJ, Obarzanek E, Cook NR, et al. Long-term weight loss and changes in blood pressure: Results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001; 134(1): 1–11.
- Morris E, Jebb SA, Oke J, et al. Effect of weight loss on cardiometabolic risk: Observational analysis of two randomised controlled trials of community weight-loss programmes. Br J Gen Pract. 2021; 71(705): e312–e319.
- Tuomilehto J, Lindström J, Eriksson J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344(18): 1343–1350.
- Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: A post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016; 4(11): 913–921.
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024 [Epub ahead of print].
- Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): An open-label, cluster-randomised trial. Lancet. 2018; 391(10120): 541–551.
- Näslund E, Stenberg E, Hofmann R, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with previous myocardial infarction and severe obesity: A nationwide cohort study. Circulation. 2021; 143(15): 1458–1467.
- Parati G, Lombardi C, Hedner J, et al. Recommendations for the management of patients with obstructive sleep apnoea and hypertension. Eur Respir J. 2013; 41(3): 523–538.
- Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: The SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016; 40(8): 1310–1319.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023; 41(12): 1874–2071.
- Hall ME, Mace HP, Hall JE. Bariatric surgery for obesity hypertension: a gateway for durable blood pressure control. J Am Coll Cardiol. 2024; 83(6): 649–651.
- Banach M, Burchardt P, Chlebus K, et al. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021. Arch Med Sci. 2021; 17(6): 1447–1547.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015; 373(1): 11–22.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021; 384(11): 989–1002.
- Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: The Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015; 3(11): 866–875.
- American Diabetes Association Professional Practice Committee. 17. Diabetes advocacy: Standards of medical care in diabetes — 2022. Diabetes Care. 2022; 45(Suppl 1): S254–S255.
- 2022 guidelines on the management of patients with diabetes. A position of diabetes poland. Curr Top Diabetes. 2022; 2(1): 1–130.
- Araszkiewicz A, Bandurska-Stankiewicz E, Borys S, et al. 2023 Guidelines on the management of patients with diabetes — a position of Diabetes Poland. Curr Top Diabetes. 2023; 3(1): 1–133.
- Kahn SE, Deanfield JE, Jeppesen OK, et al. Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the SELECT trial. Diabetes Care. 2024; 47(8): 1350–1359.
- Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39): 4043–4140.
- Schwartz MW, Seeley RJ, Zeltser LM, et al. Obesity pathogenesis: An Endocrine Society Scientific statement. Endocr Rev. 2017; 38(4): 267–296.
- Khan SS, Ning H, Wilkins JT, et al. Association of body mass index with lifetime risk of cardiovascular disease and compression of morbidity. JAMA Cardiol. 2018; 3(4): 280–287.
- Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes — state-of-the-art. Mol Metab. 2021; 46: 101102.
- Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA. 2022; 327(2): 138–150.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022; 387(3): 205–216.
- Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024; 390(15): 1394–1407.
- Borlaug BA, Kitzman DW, Davies MJ, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: A prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023; 29(9): 2358–2365.
- Butler J, Abildstrøm S, Borlaug B, et al. Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction. J Am Coll Cardiol. 2023; 82(22): 2087–2096.
- Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023; 389(12): 1069–1084.
- Petrie MC, Borlaug BA, Butler J, et al. Semaglutide and NT-proBNP in obesity-related HFpEF: Insights from the STEP-HFpEF program. J Am Coll Cardiol. 2024; 84(1): 27–40.
- Verma S, Borlaug BA, Butler J, et al. A big STEP for treatment of heart failure with preserved ejection fraction. Cell Metab. 2023; 35(10): 1681–1687.
- Butler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: A pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024; 403(10437): 1635–1648.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373–498.
- Patel KHK, Reddy RK, Sau A, et al. Obesity as a risk factor for cardiac arrhythmias. BMJ Med. 2022; 1(1): e000308.
- Morin DP, Bernard ML, Madias C, et al. The state of the art: Atrial fibrillation epidemiology, prevention, and treatment. Mayo Clin Proc. 2016; 91(12): 1778–1810.
- Feng T, Vegard M, Strand L, et al. Metabolically healthy obesity and risk for atrial fibrillation: The HUNT study. Obesity. 2019; 27(2): 332–338.
- Hatem SN, Redheuil A, Gandjbakhch E. Cardiac adipose tissue and atrial fibrillation: The perils of adiposity. Cardiovasc Res. 2016; 109(4): 502–509.
- Venteclef N, Guglielmi V, Balse E, et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J. 2015; 36(13): 795–805a.
- Sabbag A, Sidi Y, Kivity S, et al. Obesity and exercise-induced ectopic ventricular arrhythmias in apparently healthy middle aged adults. Eur J Prev Cardiol. 2016; 23(5): 511–517.
- Balla SR, Cyr DD, Lokhnygina Y, et al. Relation of risk of stroke in patients with atrial fibrillation to body mass index (from patients treated with rivaroxaban and warfarin in the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation trial). Am J Cardiol. 2017; 119(12): 1989–1996.
- Boriani G, Ruff CT, Kuder JF, et al. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019; 40(19): 1541–1550.
- Viñolas X, Freire F, Romero-Menor C, et al. Predictors of reversion to sinus rhythm previous to electrical cardioversion in patients with persistent atrial fibrillation treated with anti-arrhythmic drugs [article in Spanish]. Med Clin (Barc). 2013; 140(8): 351–355.
- Packer M. Disease-treatment interactions in the management of patients with obesity and diabetes who have atrial fibrillation: The potential mediating influence of epicardial adipose tissue. Cardiovasc Diabetol. 2019; 18(1): 121.
- Winkle RA, Mead RH, Engel G, et al. Impact of obesity on atrial fibrillation ablation: Patient characteristics, long-term outcomes, and complications. Heart Rhythm. 2017; 14(6): 819–827.
- Donnellan E, Wazni O, Kanj M, et al. Outcomes of atrial fibrillation ablation in morbidly obese patients following bariatric surgery compared with a nonobese cohort. Circ Arrhythm Electrophysiol. 2019; 12(10): e007598.
- Łoboda D, Simionescu K, Szajerska-Kurasiewicz A, et al. Cardiac arrhythmias and conduction disturbances in the obstructive sleep apnea syndrome. In a good rythm. 2018; 2(47): 10–15.
- Rymarczyk Z, Bienias P, Domienik-Karłowicz J, et al. Zmiany elektrokardiograficzne oraz zaburzenia rytmu i funkcji układu autonomicznego serca w przebiegu otyłości. Choroby Serca i Naczyń. 2015; 12(2): 96–107.
- Pathak RK, Mahajan R, Lau DH, et al. The implications of obesity for cardiac arrhythmia mechanisms and management. Can J Cardiol. 2015; 31(2): 203–210.
